Cutaneous adverse effects of the immune checkpoint inhibitors

Current Problems in Cancer

Volumn 41, Issue 2, 2017, Pages 125-128

  Collins, Lindsey K ^a   Chapman, M Shane ^a,b   Carter, Joi B ^a,b   Samie, Faramarz H ^a,b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

CTLA 4 inhibitors; Cutaneous adverse effects; Immune checkpoint inhibitors; Melanoma; PD 1 inhibitors

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 INHIBITOR; IMMUNOMODULATING AGENT; PROGRAMED CELL DEATH 1 INHIBITOR; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 INHIBITOR; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADVERSE OUTCOME; DISEASE ASSOCIATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; MANAGED CARE; PHASE 1 CLINICAL TRIAL (TOPIC); REVIEW; SKIN DISEASE; TREATMENT RESPONSE; ANIMAL; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; IMMUNOLOGY; IMMUNOMODULATION; NEOPLASM;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOMODULATION; NEOPLASMS; SKIN DISEASES;

EID: 85012941098     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2016.12.001     Document Type: Review

References (25)

1. Macdonald, J.B., Macdonald, B., Golitz, L.E., et al. Cutaneous adverse effects of targeted therapies. J Am Acad Dermatol 72:2 (2015), 221–236.
2. Greenwald, R.J., Freeman, G.J., Sharpe, A.H., The B7 family revisited. Annu Rev Immunol 23 (2005), 515–548.
3. Zimmer, L., Vuabel, J., Livingstone, E., Schadendorf, D., Side effects of systemic oncological therapies in dermatology. J Dtsch Dermatol Ges 10:7 (2012), 475–486.
4. Voskens, C.J., Goldinger, S.M., Loquai, C., et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from ipilimumab network. PLoS One., 8(1), 2013, e57345.
5. Jaber, S.H., Cowen, E.W., Haworth, L.R., Booher, S.L., Berman, D.M., Rosenberg, S.A., Hwang, S.T., Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Arch Dermatol 142:2 (2006), 166–172.
6. Minkis, K., Garden, B.C., Shenhong, W., Pulitzer, M.P., Lacouture, M.E., The risk of rash associated with ipilimumab in patients with cancer: a systemic review of the literature and meta-analysis. J Am Acad Dermatol 69:3 (2013), e121–e128.
7. Gogas, H., loannovich, J., Dafni, U., et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:4 (2006), 709–718.
8. Nordlund, J.J., Kirkwood, J.M., Forget, B.M., Milton, G., Albert, D.M., Lerner, A.B., Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 9:5 (1983), 689–696.
9. Pintova, S., Sidhu, H., Friedlander, P.A., Holcombe, R.F., Sweet׳s syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma Res 23:4 (2013), 498–501.
10. Kyllo, R.L., Parker, M.K., Rosman, I., Musiek, A.C., Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma. J Am Acad Dermatol 70:4 (2013), e85–e86.
11. Ross, R.B., North, J.P., Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab. J Am Acad Dermatol 69:5 (2013), e272–e273.
12. Tarhini, A., Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms of clinical management. Scientifica, 2013 [Article ID 857519], 2013, 19.
13. Choi, J.N., How to recognize and manage ipilimumab-induced dermatologic adverse events. The Asco Post, October 2013 [Annual Meeting].
14. Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:26 (2012), 2443–2454.
15. Hwang, S., Carlos, G., Wakade, D., et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol 74:4 (2016), 455–461.
16. Stadler, S., Weina, K., Gebhardt, C., Utikal, J., New therapeutic options for advanced non-resectable malignant melanoma. Adv Med Sci 60:1 (2014), 83–88.
17. Joseph, R.W., Cappel, M., Goedjen, B., et al. Lichenoid dermatitis in three patients with metastatic melanoma treatment with anti-PD-1 therapy. Cancer Immunol Res 3:1 (2015), 18–22.
18. Shi, V.J., Rodic, N., Gettinger, S., et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherpay. JAMA Dermatol 152:10 (2016), 1128–1136.
19. Kato, Y., Otsuka, A., Miyachi, Y., Kabashima, K., Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma. J Eur Acad Dermatol Venereol 30:10 (2015), e89–e91.
20. Matsumura, N., Ohtsuka, M., Kikuchi, N., Yamamoto, T., Exacerbation of psoriasis during nivolumab therapy for metastaticn melanoma. Acta Derm Venereol 96:20 (2016), 259–260.
21. Brahmer, J.R., Tykodi, S.S., Chow, L., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 355:26 (2012), 2455–2465.
22. McDermott, D.F., Sosman, J.A., Sznol, M., et al. Atezolizumab, an anti-programed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol 34:8 (2016), 833–842.
23. Margolin, K., The promise of molecularly targeted and immunotherapy for advanced melanoma. Curr Treat Options Oncol, 17(9), 2016, 48.
24. Yun, S., Vincelette, N., Green, M., Hendrickson, A., Abraham, I., Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systemic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med 5:7 (2016), 1481–1491.
25. Postow, M.A., Chesney, J., Pavlick, A., et al. Nivolumab and ipilumamab versus ipilimumab in untreated melanoma. N Engl Med 372:21 (2015), 2006–2016.